| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| D Ferone, E Resmini, L Bocca, M Giusti, A Barreca, F Minut. Current diagnostic guidelines for biochemical diagnosis of acromegaly. Minerva endocrinologica. vol 29. issue 4. 2005-04-14. PMID:15765030. |
acromegaly is a rare and chronic disease that, in the majority of cases, is due to the presence of a benign growth hormone (gh)-producing tumor of the pituitary. |
2005-04-14 |
2023-08-12 |
human |
| M Arosio, C L Ronchi, P Epaminonda, S di Lembo, G Add. New therapeutic options for acromegaly. Minerva endocrinologica. vol 29. issue 4. 2005-04-14. PMID:15765031. |
acromegaly is a slowly developing disfiguring disease characterized by chronic growth hormone (gh) and insulin-like growth factor-i (igf-i) excess and caused by a pituitary somatotroph adenoma. |
2005-04-14 |
2023-08-12 |
Not clear |
| M Arosio, C L Ronchi, P Epaminonda, S di Lembo, G Add. New therapeutic options for acromegaly. Minerva endocrinologica. vol 29. issue 4. 2005-04-14. PMID:15765031. |
the morbidity and excess mortality of acromegaly are usually the consequence of the metabolic actions of excess gh and igf-i secretion, while only in rare patients mortality is due to the mass effects of the pituitary tumour. |
2005-04-14 |
2023-08-12 |
Not clear |
| M Arosio, C L Ronchi, P Epaminonda, S di Lembo, G Add. New therapeutic options for acromegaly. Minerva endocrinologica. vol 29. issue 4. 2005-04-14. PMID:15765031. |
since, serum igf-i concentrations within age-adjusted normal range, and a tight gh control have to be achieved to normalize life-expectancy in these patients, an aggressive, and often multi-modality treatment is required for acromegaly. |
2005-04-14 |
2023-08-12 |
Not clear |
| P Chanson, S Salenav. Diagnosis and treatment of pituitary adenomas. Minerva endocrinologica. vol 29. issue 4. 2005-04-14. PMID:15765032. |
pituitary tumors cause symptoms by secreting hormones (prolactin, prl, responsible for amenorrhea-galactorrhea in women and decreased libido in men; growth hormone, gh, responsible for acromegaly; adrenocorticotropic hormone, acth, responsible for cushing's syndrome; thyroid-stimulating hormone, tsh, responsible for hyperthyroidism), depressing the secretion of hormones (hypopituitarism), or by mass-related effects (headaches, visual field abnormalities...). |
2005-04-14 |
2023-08-12 |
Not clear |
| Sigrid Jehle, Carlos M Reyes, Robert E Sundeen, Pamela U Fred. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. The Journal of clinical endocrinology and metabolism. vol 90. issue 3. 2005-04-12. PMID:15585549. |
igf-i levels normalize in the majority of patients with acromegaly treated with the gh receptor antagonist pegvisomant. |
2005-04-12 |
2023-08-12 |
Not clear |
| J Isgaar. Cardiovascular disease and risk factors: the role of growth hormone. Hormone research. vol 62 Suppl 4. 2005-04-12. PMID:15591764. |
clinical studies in patients with acromegaly have shown that growth hormone (gh) exerts both short- and long-term effects on the structure and function of the heart. |
2005-04-12 |
2023-08-12 |
Not clear |
| R Cozzi, R Attanasio, S Grottoli, G Pagani, P Loli, V Gasco, A M Pedroncelli, M Montini, E Ghig. Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease? Journal of endocrinological investigation. vol 27. issue 11. 2005-04-05. PMID:15754736. |
treatment of acromegaly with ss analogues: should gh and igf-i target levels be lowered to assert a tight control of the disease? |
2005-04-05 |
2023-08-12 |
Not clear |
| W M Drake, R A Loureiro, C Parkinson, J P Monson, G M Besser, P J Traine. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant. European journal of endocrinology. vol 152. issue 1. 2005-03-31. PMID:15762186. |
pegvisomant, a modified growth hormone (gh) molecule, is a novel medical therapy for acromegaly that functions as a gh receptor antagonist. |
2005-03-31 |
2023-08-12 |
Not clear |
| Nienke R Biermasz, Neveen A T Hamdy, Alberto M Pereira, Johannes A Romijn, Ferdinand Roelfsem. Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly. European journal of endocrinology. vol 152. issue 1. 2005-03-31. PMID:15762187. |
long-term maintenance of the anabolic effects of gh on the skeleton in successfully treated patients with acromegaly. |
2005-03-31 |
2023-08-12 |
Not clear |
| Nienke R Biermasz, Neveen A T Hamdy, Alberto M Pereira, Johannes A Romijn, Ferdinand Roelfsem. Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly. European journal of endocrinology. vol 152. issue 1. 2005-03-31. PMID:15762187. |
in acromegaly, the skeletal effects of chronic gh excess have been mainly addressed by evaluating bone mineral density (bmd). |
2005-03-31 |
2023-08-12 |
Not clear |
| Nienke R Biermasz, Neveen A T Hamdy, Alberto M Pereira, Johannes A Romijn, Ferdinand Roelfsem. Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly. European journal of endocrinology. vol 152. issue 1. 2005-03-31. PMID:15762187. |
whether the positive effect of gh excess on bone mass is maintained in the long term after clinical and biochemical cure of acromegaly remains to be established. |
2005-03-31 |
2023-08-12 |
Not clear |
| P J Jenkins, M Emery, S J Howling, J Evanson, G M Besser, J P Monso. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR. Hormone research. vol 62. issue 5. 2005-03-29. PMID:15477693. |
this study prospectively determined the effects of the depot somatostatin analogue octreotide lar on pituitary tumour size, gh and igf-i levels and clinical symptoms in a cohort of previously untreated patients with acromegaly. |
2005-03-29 |
2023-08-12 |
Not clear |
| Thor Uelan. Bone metabolism in relation to alterations in systemic growth hormone. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 14. issue 6. 2005-03-29. PMID:15519248. |
acromegaly, gh deficiency, postmenopausal osteoporosis) and experimental models (i.e. |
2005-03-29 |
2023-08-12 |
mouse |
| Izumi Fukuda, Naomi Hizuka, Yukiko Ishikawa, Emina Itoh, Kumiko Yasumoto, Yuko Murakami, Akira Sata, Junko Tsukada, Makiko Kurimoto, Yumiko Okubo, Kazue Takan. Serum adiponectin levels in adult growth hormone deficiency and acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 14. issue 6. 2005-03-29. PMID:15519253. |
in this study, we measured serum adiponectin levels in patients with either adult ghd or acromegaly to clarify the impact of gh secretory states on the regulation of serum adiponectin levels. |
2005-03-29 |
2023-08-12 |
human |
| Izumi Fukuda, Naomi Hizuka, Yukiko Ishikawa, Emina Itoh, Kumiko Yasumoto, Yuko Murakami, Akira Sata, Junko Tsukada, Makiko Kurimoto, Yumiko Okubo, Kazue Takan. Serum adiponectin levels in adult growth hormone deficiency and acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 14. issue 6. 2005-03-29. PMID:15519253. |
in patients with acromegaly, the levels of circulating adiponectin showed an inverse correlation with serum igf-i levels (r(s) = -0.34, p < 0.05), but not with basal gh levels. |
2005-03-29 |
2023-08-12 |
human |
| Izumi Fukuda, Naomi Hizuka, Yukiko Ishikawa, Emina Itoh, Kumiko Yasumoto, Yuko Murakami, Akira Sata, Junko Tsukada, Makiko Kurimoto, Yumiko Okubo, Kazue Takan. Serum adiponectin levels in adult growth hormone deficiency and acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 14. issue 6. 2005-03-29. PMID:15519253. |
the different relationship between adiponectin and quicki observed in the adult ghd and acromegaly groups presumably reflects differences in the mechanisms of insulin resistance under states of gh deficiency or excess. |
2005-03-29 |
2023-08-12 |
human |
| Alberto M Pereira, Nienke R Biermasz, Ferdinand Roelfsema, Johannes A Romij. Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance. Treatments in endocrinology. vol 4. issue 1. 2005-03-17. PMID:15649100. |
in acromegaly, preliminary observations on new octreotide analogs with greater specificity for somatostatin-receptor subtypes indicate that these compounds achieve better control of gh hypersecretion than octreotide, but may also negatively influence insulin release. |
2005-03-17 |
2023-08-12 |
Not clear |
| Antonio Ciccarelli, Adrian Daly, Albert Becker. Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium. Treatments in endocrinology. vol 3. issue 2. 2005-03-17. PMID:15743103. |
furthermore, lanreotide autogel is at least as efficacious as the other somatostatin analogs in lowering growth hormone (gh) and insulin-like growth factor-1 (igf-1) levels in the majority and in restoring safe gh and age-normalized igf-1 levels in about 50-60% of patients with acromegaly. |
2005-03-17 |
2023-08-12 |
Not clear |
| Giovanni Vitale, Rosario Pivonello, Gaetano Lombardi, Annamaria Cola. Cardiac abnormalities in acromegaly. Pathophysiology and implications for management. Treatments in endocrinology. vol 3. issue 5. 2005-02-18. PMID:15330678. |
in the early phase of acromegaly the excess of gh and igf-i induces a hyperkinetic syndrome, characterized by increased heart rate and increased systolic output. |
2005-02-18 |
2023-08-12 |
Not clear |